
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Each year in November, December, and January our office is inundated with calendars from pharmaceutical companies. I collect them and give them out to my asthma patients.






